Meghna Das Thakur
Gilead Sciences (United States) · 64 works · 3,476 citations · h-index 21
Top works
- Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance
- Peripheral T cell expansion predicts tumour infiltration and clinical response
- Ajuba LIM Proteins Are Negative Regulators of the Hippo Signaling Pathway
- Molecular, Pathological, Radiological, and Immune Profiling of Non-brainstem Pediatric High-Grade Glioma from the HERBY Phase II Randomized Trial
- Clinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC).
- Ligand-Independent EPHA2 Signaling Drives the Adoption of a Targeted Therapy–Mediated Metastatic Melanoma Phenotype
- Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS- mutated non-small cell lung cancer with STK11 , KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial
- Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors
- Tumor Fraction Correlates With Detection of Actionable Variants Across > 23,000 Circulating Tumor DNA Samples
- The Evolution of Melanoma Resistance Reveals Therapeutic Opportunities
- A Multifunctional Lentiviral-Based Gene Knockdown with Concurrent Rescue that Controls for Off-Target Effects of RNAi
- Molecular Pathways: Response and Resistance to BRAF and MEK Inhibitors in BRAFV600E Tumors
- Profiling the heterogeneity of colorectal cancer consensus molecular subtypes using spatial transcriptomics
- Endothelial Cell Migration on RGD-Peptide-Containing PEG Hydrogels in the Presence of Sphingosine 1-Phosphate
- 2O IMpower010: Biomarkers of disease-free survival (DFS) in a phase III study of atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy in stage IB-IIIA NSCLC
- Epigenetic promoter alterations in GI tumour immune-editing and resistance to immune checkpoint inhibition
- BRIM‐P: A phase I, open‐label, multicenter, dose‐escalation study of vemurafenib in pediatric patients with surgically incurable, BRAF mutation‐positive melanoma
- CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials
- Clinical and exploratory biomarker findings from the MODUL trial (Cohorts 1, 3 and 4) of biomarker-driven maintenance therapy for metastatic colorectal cancer
- A phase I/II study of atezolizumab in pediatric and young adult patients with refractory/relapsed solid tumors (iMATRIX-Atezolizumab).